Quince Therapeutics (QNCX) said late Tuesday that the enrollment in its phase 3 clinical trial of the neurological effects of eDSP system on Ataxia-Telangiectasia patients has exceeded 75%.
EDSP is comprised of dexamethasone sodium phosphate encapsulated in a patient's own red blood cells.
A total of 76 participants have been enrolled, including 65 participants in the six- to nine-year-old primary analysis population and 11 participants aged 10 years or above, the company said.
The company said it plans to submit a new drug application to the US Food and Drug Administration in H2 2026, subject to a positive outcome of the trial.
The company said it received the FDA's fast track designation for eDSP system for the treatment of patients with Ataxia-Telangiectasia, a rare neurodegenerative disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.